Acadia Pharmaceuticals (ACAD) Change in Cash (2010 - 2026)

Acadia Pharmaceuticals' Change in Cash history runs 17 years deep, the most recent figure standing at $104.5 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 202.58% year-over-year to $104.5 million in Q1 2026; TTM through Mar 2026 was $63.6 million, a 298.67% increase from a year earlier, with the FY2025 full-year figure at -$142.8 million, down 206.64% from the prior year.
• Change in Cash climbed to $104.5 million in Q1 2026 per ACAD's latest filing, from -$81.9 million in the prior quarter.
• Across five years, Change in Cash topped out at $176.0 million in Q1 2023 and bottomed at -$180.6 million in Q2 2023.
• The 5-year median for Change in Cash is $4.4 million (2025), against an average of $8.1 million.
• Across the five-year window, Change in Cash surged 366.86% in 2022 and plunged 733.35% in 2025, its largest moves.
• Year by year, Change in Cash stood at -$40.0 million in 2022, then soared by 326.18% to $90.5 million in 2023, then surged by 81.77% to $164.4 million in 2024, then slumped by 149.82% to -$81.9 million in 2025, then soared by 227.57% to $104.5 million in 2026.
• Per Business Quant, the three latest ACAD Change in Cash figures stand at $104.5 million (Q1 2026), -$81.9 million (Q4 2025), and $4.4 million (Q3 2025).